NC

About Nas Care

Nas Care is a private limited company (BV/SRL) based in Zaventem, founded in 2023. Its main activity is classified as "Activiteiten van verpleegkundigen en verloskundigen". For the 2023 financial year, Nas Care reported a profit of €10,751. Revenue was not published, which is common for abbreviated accounts. The gross margin came to €13,494. Equity stands at €14,751, a solvency ratio of 54%.

Juridical situation
Normal situation
Company number
0800.487.154
Founding date
Founded on 06-04-2023
EUID number
BEKBOBCE.0800.487.154
Type of enterprise
Rechtspersoon
Location
Leuvensesteenweg 246/1 Zaventem 1932
Juridical form
BV — Private limited company (BV/SRL)
Signals
Profitable
Low risk
Good liquidity
Positive cashflow
Positive EBITDA

Financial ratios

Profit
€ 11K
Equity
€ 15K
Gross margin
€ 13K
Health
Solvability > 25%
53.8%
Liquidity > 1.0
2.15
Profitability > 0%
72.9%
2023
Gross margin
€ 13K
EBITDA
€ 13K
Profit
€ 11K
Equity
€ 15K
Solvability
53.78%
Debt
€ 13K
Cash
€ 18K

Frequently asked questions

Answers to the most common questions about Nas Care, based on official government data and the filed annual accounts.

What is the VAT number of Nas Care?

The VAT number of Nas Care is BE0800.487.154.

When was Nas Care established?

Nas Care was founded in 06-04-2023.

What is the official address of Nas Care?

The official address of Nas Care is Leuvensesteenweg 246/1 Zaventem 1932.

What is the legal form of Nas Care?

The juridical form of Nas Care is Private limited company (BV/SRL).

What is the annual revenue of Nas Care?

The 2023 accounts of Nas Care do not report revenue. Smaller companies that file abbreviated accounts are not required to publish it.

Is Nas Care a reliable company?

Nas Care is a registered Rechtspersoon with company number 0800.487.154 and can be verified through the official CBE database.

What is the credit limit of Nas Care?

The estimated credit limit of Nas Care is €15,157.

Is Nas Care still active?

Nas Care currently has the status "Normal situation" and is active.

Further reading

View all insights

Sources